Neuropathology of central norepinephrine in psychiatric disorders: Postmortem research

Brain Norepinephrine: Neurobiology and Therapeutics

Volumn , Issue , 2007, Pages 341-362

  Ordway, Gregory A ^a  

^a East Tennessee State University   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41949134279     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511544156.012     Document Type: Chapter

References (79)

1. Ordway, G. A. and Klimek, V.Noradrenergic pathology in psychiatric disorders: postmortem studies. CNS Spectr., 6 (2001), 697-703.
2. Lewis, D. A. The human brain revisited: opportunities and challenges in postmortem studies of psychiatric disorders. Neuropsychopharmacology, 26: 2 (2002), 143-154.
3. Stockmeier, C. A. Involvement of serotonin in depression: evidence from postmortem and imaging studies of serotonin receptors and the serotonin transporter. J. Psychiatr. Res., 37: 5 (2003), 357-373.
4. Salomon, R. M., Miller, H. L., Krystal, J. H., Heninger, G. R. and Charney, D. S. Lack of behavioral effects of monoamine depletion in healthy subjects. Biol. Psychiatry, 41: 1 (1997) 58-64.
5. Berman, R. M., Narasimhan, M., Miller, H. L. et al. Transient depressive relapse induced by catecholamine depletion: potential phenotypic vulnerability marker? Arch. Gen. Psychiatry, 56: 5 (1999), 395-403.
6. Charney, D. S. Monoamine dysfunction and the pathophysiology and treatment of depression. J. Clin. Psychiatry, 59: Suppl. 14 (1998), 11-14.
7. Rich, C. L., Young, D., Fowler, R. C. San Diego suicide study. Arch.Gen. Psychiatry, 43 (1986), 577-582.
8. Gross-Isseroff, R., Biegon, A., Voet, H. and Weizman, A. The suicide brain: a review of postmortem receptor/transporter binding studies. Neurosci. Biobehav. Rev., 22: 5 (1998), 653-661.
9. Meana, J. J. and Garcia-Sevilla, J. A. Increased alpha 2-adrenoceptor density in the frontal cortex of depressed suicide victims. J. Neural Transm., 70: 3-4 (1987), 377-381.
10. Gonzalez, A. M., Pascual, J., Meana, J. J. et al. Autoradiographic demonstration of increased alpha 2-adrenoceptor agonist binding sites in the hippocampus and frontal cortex of depressed suicide victims. J. Neurochem., 63: 1 (1994), 256-265.
11. Callado, L. F., Meana, J. J., Grijalba, B. et al. Selective increase of alpha2A-adrenoceptor agonist binding sites in brains of depressed suicide victims. J. Neurochem., 70: 3 (1998), 1114-1123.
12. Gonzalez-Maeso, J., Rodriguez-Puertas, R., Meana, J. J., Garcia-Sevilla, J. A. and Guimon, J. Neurotransmitter receptor-mediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of alpha(2A)-adrenoceptors. Mol. Psychiatry, 7: 7 (2002), 755-767.
13. U'Prichard, D. C., Bechtel, W.D., Rouot, B. M. and Snyder, S. H. Multiple apparent alphanoradrenergic receptor binding sites in rat brain: effect of 6-hydroxydopamine. Mol. Pharmacol., 16 (1979), 47-60.
14. Gross, G., Gothert, M., Glapa, U., Engel, G. and Schumann, H. J. Lesioning of serotoninergic and noradrenergic nerve fibres of the rat brain does not decrease binding of 3H-clonidine and 3H-rauwolscine to cortical membranes. Naunyn-Schmiedeberg's Arch. Pharmacol., 328 (1985), 229-235.
15. Weiss, J. M., Goodman, P. A., Losito, B. G. et al. Behavioral depression produced by an uncontrollable stressor: relationship to norepinephrine, dopamine, and serotonin levels in various regions of rat brain. Brain. Res. Rev., 3 (1981), 167-205.
16. Danysz, W., Kostowski, W.andHauptmann, M.Evidence for the locus coeruleus involvement in desipramine action in animal models of depression. Pol. J. Pharmacol. Pharm., 37: 6 (1985), 855-864.
17. Wolfe, B. B., Harden, T. K., Sporn, J. R. and Molinoff, P. B. Presynaptic modulation of beta adrenergic receptors in rat cerebral cortex after treatment with antidepressants. J. Pharmacol. Exp. Ther., 207: 2 (1978), 446-457.
18. Biegon, A. and Rainbow, T. C. Localization and characterization of [3H]desmethylimipramine binding sites in rat brain by quantitative autoradiography. J. Neurosci., 3: 5 (1983), 1069-1076.
19. Ordway, G. A., Stockmeier, C. A., Cason, G.W. and Klimek, V. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J. Neurosci., 17 (1997), 1710-1719.
20. Richards, J. G., Saura, J., Ulrich, J. and Da Prada, M. Molecular neuroanatomy of monoamine oxidases in human brainstem. Psychopharmacology (Berl.), 106: Suppl. (1992), S21-S23.
21. Klimek, V. and Ordway, G. A. Distribution of alpha2-adrenoceptors in the human locus coeruleus. Brain Res., 741 (1996), 263-274.
22. Cortes, R., Soriano, E., Pazos, A., Probst, A. and Palacios, J. M. Autoradiography of antidepressant binding sites in the human brain: localization using [3H]imipramine and [3H]paroxetine. Neuroscience, 27: 2 (1988), 473-496.
23. Klimek, V., Stockmeier, C. A., Overholser, J. C. et al. Serotonin transporter andMAO-B levels in monoamine nuclei of the human brain stem are normal in major depression. J. Psychiatr. Res., 37 (2003), 387-397.
24. Nestler, E. J., McMahon, A., Sabban, E. L., Tallman, J. F. and Duman, R. S. Chronic antidepressant administration decreases the expression of tyrosine hydroxylase in the rat locus coeruleus. Proc. Natl. Acad. Sci. U. S. A., 87: 19 (1990), 7522-7526.
25. Szabo, S. T., de Montigny, C. and Blier, P. Progressive attenuation of the firing activity of locus coeruleus noradrenergic neurons by sustained administration of selective serotonin reuptake inhibitors. Int. J. Neuropsychopharmacol., 3: 1 (2000), 1-11.
26. Grant, M. M. and Weiss, J. M. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity. Biol. Psychiatry, 49: 2 (2001), 117-129.
27. Ordway, G. A., Widdowson, P. S., Smith, K. and Halaris, A. E. Agonist binding to alpha2 adrenoceptors is elevated in the locus coeruleus from victims of suicide. J. Neurochem., 63 (1994), 617-624.
28. Ordway, G. A., Streator-Smith, K. and Haycock, J. W. Elevated tyrosine hydroxylase in the locus coeruleus of suicide victims. J. Neurochem., 62 (1994), 680-685.
29. Ordway, G. A., Schenk, J., Meltzer, H. Y. et al. Elevated agonist binding to alpha2-adrenoceptors in the locus coeruleus in major depression. Biol. Psychiatry, 53: (2003), 315-323.
30. Zhu, M.-Y., Klimek, V., Dilley, G. E. et al. Elevated levels of tyrosine hydroxylase in the locus coeruleus in major depression. Biol. Psychiatry, 46 (1999), 1275-1286.
31. Klimek, V., Stockmeier, C. A., Overholser, J. et al. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J. Neurosci., 17 (1997), 8451-8458.
32. Ordway, G. A., Farley, J. T., Dilley, G. E. et al. Quantitative distribution of monoamine oxidase A in brainstem monoamine nuclei is normal in major depression. Brain Res., 847 (1999), 71-79.
33. Klimek, V., Stockmeier, C. A., Overholser, J. C. et al. Serotonin transporter andMAO-B levels in monoamine nuclei of the human brain stem are normal in major depression. J. Psychiatr. Res., 37 (2003), 387-397.
34. Biegon, A. and Fieldust, S.Reduced tyrosine hydroxylaseimmunoreactivity in locus coeruleus of suicide victims. Synapse, 10 (1992), 79-82.
35. Baumann, B., Danos, P., Diekmann, S. et al. Tyrosine hydroxylase immunoreactivity in the locus coeruleus is reduced in depressed non-suicidal patients but normal in depressed suicide patients. Eur. Arch. Psychiatry Clin. Neurosci., 249: 4 (1999), 212-219.
36. Melia, K. R., Rasmussen, K., Terwilliger, R. Z. et al. Coordinate regulation of the cyclic AMP system with firing rate and expression of tyrosine hydroxylase in the rat locus coeruleus: effects of chronic stress and drug treatments. J. Neurochem., 58 (1992), 494-502.
37. Cubells, J. F., Kim, K. S., Baker, H. et al. Differential in vivo regulation of mRNA encoding the norepinephrine transporter and tyrosine hydroxylase in rat adrenal medulla and locus coeruleus. J. Neurochem., 65 (1995), 502-509.
38. Lee, C.-M., Javitch, J. A. and Snyder, S. H. Recognition sites for norepinephrine uptake: regulation by neurotransmitter. Science, 220 (1983), 626-629.
39. Weiss, J. M., Glazer, H. I. and Pohorecky, L. A. Coping behavior and neurochemical changes: an alternative explanation for the original "learned helplessness" experiments. In Animal Models in Human Psychobiology, ed. S. Kling (New York: Plenum, 1976) pp. 133-145.
40. Torda, T., Kvetnansky, R. and Petrikova, M. Effect of repeated immobilization stress on central and peripheral adrenoceptors in rats. Endocrinol. Exp., 19: 3 (1985), 157-163.
41. Zafar, H. M., Pare, W. P. and Tejani-Butt, S. M. Effect of acute or repeated stress on behavior and brain norepinephrine system inWistar-Kyoto (WKY) rats. Brain Res. Bull., 44: 3 (1997), 289-295.
42. Ordway, G. A., Klimek, V. and Mann, J. J. Neurocircuitry of mood disorder. In Neuropsychopharmacology: The Fifth Generation of Progress, ed. K. L. Davis, D. Charney, J. T. Coyle and C. Nemeroff. (Philadelphia: LippincottWilliams &Wilkins, 2002) pp. 1051-1064.
43. Brady, L. S., Gold, P.W., Herkenham, M., Lynn, A. B. andWhitfield, H. J. The antidepressants fluoxetine, idazoxan, and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res., 572 (1992), 117-125.
44. Ordway, G. A. and Szebeni, K. Effect of olanzapine on tyrosine hydroxylase in the rat locus coeruleus. Int. J. Neuropsychopharmacol., 7 (2004), 1-7.
45. Schultzberg, M., Austin, M. C., Crawley, J. N. and Paul, S. M. Repeated administration of desmethylimipramine blocks reserpine-induced increase in tyrosine hydroxylase mRNA in locus coeruleus neurons of the rat. Mol. Brain Res., 10 (1991), 307-314.
46. Melia, K. R., Nestler, E. J. and Duman, R. S. Chronic imipramine treatment normalizes levels of tyrosine hydroxylase in the locus coeruleus of chronically stressed rats. Psychopharmacology (Berl.), 108:1-2 (1992), 23-26.
47. Kovachich, G. B., Frazer, A. and Aronson, C. E. Effect of chronic administration of antidepressants on alpha 2-adrenoceptors in the locus coeruleus and its projection fields in rat brain determined by quantitative autoradiography. Neuropsychopharmacology, 8 (1993), 57-65.
48. Bauer, M. E. and Tejani-Butt, S. M. Effects of repeated administration of desipramine or electroconvulsive shock on norepinephrine uptake sites measured by [3H]nisoxetine autoradiography. Brain Res., 582 (1992), 208-214.
49. Holmes, A., Heilig, M., Rupniak, N. M., Steckler, T. and Griebel, G. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders. Trends Pharmacol. Sci., 24: 11 (2003), 580-588.
50. Bissette, G., Klimek, V., Pan, J., Stockmeier, C. A. and Ordway, G. A. Elevated concentrations of CRF in the locus coeruleus of depressed subjects. Neuropsychopharmacology, 28 (2003), 1328-1335.
51. Chappell, P. B., Smith, M. A., Kilts, C.D. et al. Alterations in corticotropin-releasing factorlike immunoreactivity in discrete rat brain regions after acute and chronic stress. J. Neurosci., 6 (1986), 2908-2914.
52. Karolewicz, B., Szebeni, K., Stockmeier, C. A. et al. Low nNOS protein in the locus coeruleus in major depression. J. Neurochem., 91 (2004), 1057-1066.
53. Karolewicz, B., Stockmeier, C. A. and Ordway, G. A. Elevated levels of the NR2C subunit of the NMDA receptor in the locus coeruleus in depression. Neuropsychopharmacology, 30 (2005), 1557-1567.
54. Fitzgerald, L.W., Ortiz, J., Hamedani, A. G. and Nestler, E. J. Drugs of abuse and stress increase the expression of GluR1 andNMDAR1 glutamate receptor subunits in the rat ventral tegmental area: common adaptations among cross-sensitizing agents. J.Neurosci., 16 (1996), 274-282.
55. Bartanusz, V., Aubry, J. M., Pagliusi, S. et al. Stress-induced changes in messenger RNA levels of N-methyl-D-aspartate and AMPA receptor subunits in selected regions of the rat hippocampus and hypothalamus. Neuroscience, 66 (1995), 247-252.
56. Zhu, H., Karolewicz, B., Nail, E. et al. Analysis of GABAA receptors in the locus coeruleus in major depression. Soc. Neurosci. Abstr., (2004), program No. 799. 15.
57. Crow, T. J., Cross, A. J., Cooper, S. J. et al. Neurotransmitter receptors and monoamine metabolites in the brains of patients with Alzheimer-type dementia and depression, and suicides. Neuropharmacology, 23 (1984), 1561-1569.
58. Ferrier, I. N., McKeith, I. G., Cross, A. J. et al. Postmortem neurochemical studies in depression. Ann. N. Y. Acad. Sci., 487 (1986), 128-142.
59. Klimek, V., Rajkowska, G., Luker, S. N. et al. Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology, 21 (1999), 69-81.
60. Garcia-Sevilla, J. A., Escriba, P.V., Ozaita, A. et al. Up-regulation of immunolabeled alpha2Aadrenoceptors, Gi coupling proteins, and regulatory receptor kinases in the prefrontal cortex of depressed suicides. J. Neurochem., 72: 1 (1999), 282-291.
61. Ribas, C., Miralles, A., Busquets, X. and Garcia-Sevilla, J. A. Brain alpha(2)-adrenoceptors in monoamine-depleted rats: increased receptor density, Gcoupling proteins, receptor turnover and receptor mRNA. Br. J. Pharmacol., 132: 7 (2001), 1467-1476.
62. Mann, J. J., Stanley, M., McBride, P. A. and McEwen, B. S. Increased serotonin2 and betaadrenergic receptor binding in the frontal cortices of suicide victims. Arch. Gen. Psychiatry, 43: 10 (1986), 954-959.
63. Biegon, A. and Israeli, M. Regionally selective increases in beta-adrenergic receptor density in the brains of suicide victims. Brain Res., 442: 1 (1988), 199-203.
64. Stockmeier, C. A. and Meltzer, H. Y. Beta-adrenergic receptor binding in frontal cortex of suicide victims. Biol. Psychiatry, 29: 2 (1991), 183-191.
65. Little, K. Y., Clark, T. B., Ranc, J. and Duncan G. E. Beta-adrenergic receptor binding in frontal cortex from suicide victims. Biol. Psychiatry, 34: 9 (1993), 596-605.
66. De Paermentier, F., Cheetham, S. C., Crompton, M. R., Katona, C. L. andHorton, R. W. Brain beta-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res., 525: 1 (1990), 171-77.
67. Yamamoto, K. andHornykiewicz, O. Proposal for a noradrenaline hypothesis of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 28: 5 (2004), 913-922.
68. Wise, C.D. and Stein, L. Dopamine beta-hydroxylase deficits in the brains of schizophrenic patients. Science, 181: 97 (1973), 344-347.
69. Wyatt, R. J., Schwartz, M. A., Erdelyi, E.andBarchas, J. D.Dopaminebeta-hydroxylase activity in brains of chronic schizophrenic patients. Science, 187: 4174 (1975), 368-370.
70. Farley, I. J., Price, K. S., McCullough, E. et al. Norepinephrine in chronic paranoid schizophrenia: above-normal levels in limbic forebrain. Science, 200: 4340 (1978), 456-458.
71. Winblad, B., Bucht, G., Gottfries, C. G. and Roos, B. E. Monoamines and monoamine metabolites in brains from demented schizophrenics. Acta Psychiatr. Scand., 60: 1 (1979), 17-28.
72. Crow, T. J., Baker, H. F., Cross, A. J. et al. Monoamine mechanisms in chronic schizophrenia: post-mortem neurochemical findings. Br. J. Psychiatry, 134 (1979), 249-256.
73. Bird, E. D., Spokes, E. G. and Iversen, L. L. Dopamine and noradrenaline in post-mortem brain in Huntington's disease and schizophrenic illness. Acta Psychiatr. Scand. Suppl., 280 (1980), 63-73.
74. Bridge, T. P., Kleinman, J. E., Karoum, F. andWyatt, R. J. Postmortem central catecholamines and antemortem cognitive impairment in elderly schizophrenics and controls. Neuropsychobiology, 14: 2 (1985), 57-61.
75. Friedman, J. I., Temporini, H. and Davis, K. L. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry, 45: 1 (1999), 1-16.
76. Bridge, T. P., Kleinman, J. E., Soldo, B. J. and Karoum, F. Central catecholamines, cognitive impairment, and affective state in elderly schizophrenics and controls. Biol. Psychiatry, 22: 2 (1987), 139-147.
77. Bennett, J. P. Jr., Enna, S. J., Bylund, D. B. et al. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch. Gen. Psychiatry, 36: 9 (1979), 927-934.
78. Joyce, J. N., Lexow, N., Kim, S. J. et al. Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: alterations in limbic regions of schizophrenics. Synapse, 10: 3 (1992), 228-246.
79. Dean, B. [3H]RX821002 in human dorsolateral prefrontal cortex: no changes in postmortem tissue from subjects with schizophrenia. Psychiatry Res., 119: 1-2 (2003), 25-31.